Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes trial The SOUL Study orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes trial The SOUL Study ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes trial The SOUL Study, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes trial The SOUL Study in your area.
Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
29.60
Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy
29.13
Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme - Thethi - 2020 - Diabetes, Obesity and Metabolism
27.81
NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Read the full trial results at NEJM.org (link in bio). , , #ACC25 #Cardiology #ClinicalTrials #NEJM
29.33
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
21.39
Results of SOUL Trial with Oral Semaglutide
29.58
An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25
22.19
